lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Mrs. Fenghua Wu at Hubei university of chinese medcine, China.

Mrs. Fenghua Wu is a distinguished researcher and educator with a doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🎓. She specializes in physiology and oncology, focusing on the tumor microenvironment and tumor immunology 🔬. Her groundbreaking research explores the regulatory mechanisms of natural and traditional Chinese medicines in cancer treatment 🌿. As a principal investigator for the National Natural Science Foundation of China, she has published extensively in SCI-indexed journals 📚. Honored as a “Teaching Expert” and COVID-19 frontline contributor 🏅, she also serves as a Guest Editor for Frontiers in Immunology.

Publication Profile 

Scopus

Education

Mrs. Fenghua Wu earned her doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🏥. She currently teaches physiology and is actively engaged in oncology research 🔬 at her institution. Her work focuses on exploring cancer biology and its treatment mechanisms. As a leading scientist, she has served as the principal investigator for prestigious projects funded by the National Natural Science Foundation of China 🇨🇳. Her academic dedication and scientific contributions reflect her commitment to advancing knowledge in the field of cancer research and education.

Professional Memberships

Mrs. Fenghua Wu is a proud member of the Chinese Anti-Cancer Association (CACA) 🧬, a prestigious national organization committed to advancing cancer research, treatment, and public health awareness in China 🇨🇳. Her affiliation with CACA underscores her dedication to the oncology field and her active participation in collaborative efforts aimed at combating cancer through scientific innovation and knowledge exchange 🔬. As part of this professional body, she stays connected with leading experts, contributes to cancer-related initiatives, and continuously enhances her expertise to benefit patients and students alike.

Research Focus 

Mrs. Fenghua Wu’s research focus lies at the intersection of tumor immunology, traditional Chinese medicine, and molecular oncology 🧬. She explores how natural compounds—such as dihydroartemisinin and capsaicin—can modulate immune responses and inhibit cancer progression, particularly in breast cancer and tongue squamous cell carcinoma (TSCC) 🎯. Her studies often center on critical pathways like TNF-α, PI3K/AKT/mTOR, and TGF-β1, highlighting her commitment to advancing immunotherapy and targeted therapies 🧪. Her category of research can be broadly classified under Cancer Pharmacology, Immuno-Oncology, and Natural Product-Based Therapeutics.

Publication Top Notes

  • Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer
  • Capsaicin combined with cisplatin inhibits TGF-β1-induced EMT and TSCC cells migration via the Claudin-1/PI3K/AKT/mTOR signaling pathway

Angela Sardaro | Immunotherapy | Excellence in Research

Published on by Top Pharmaceutical

Angela Sardaro | Immunotherapy | Excellence in Research

Assoc. Prof. Dr. Angela Sardaro at ASL Lecce, Italy.

Assoc. Prof. Dr. Angela Sardaro is a distinguished Italian academic and medical professional specializing in Radiotherapy and Diagnostic Imaging. She has served as a professor at the University of Bari Aldo Moro, coordinating degree programs and teaching across multiple disciplines, including Radiology, Oncology, and Medical Imaging. With over 15 years of academic experience, she has guided numerous theses and led scientific seminars. Dr. Sardaro’s prolific research output includes 81 indexed publications, an h-index of 15, and 842 citations 📈. Her contributions extend globally, with collaborations in the UK and Italy, reinforcing her impact in oncology and radiological science.

Publication Profile 

scopus

Education

Assoc. Prof. Dr. Angela Sardaro has demonstrated outstanding commitment to medical education 👩‍⚕️📚, coordinating the Degree Course in Radiologic Imaging and Radiotherapy Techniques at the University of Bari Aldo Moro 🎓. With over 15 years of teaching experience across various undergraduate and postgraduate programs, she has taught core disciplines like Radiotherapy, Radiobiology, and Diagnostic Imaging 🧬🔬. Her academic service spans doctoral programs, master’s training in pain therapy, and prestigious collaborations with institutions in Florence and the UK 🇮🇹🇬🇧. Dr. Sardaro has delivered 1,440 hours of lectures and 4,160 hours of professional training 📊, shaping future generations in radiological sciences.

Experience

Assoc. Prof. Dr. Angela Sardaro has made a remarkable impact on clinical education and hands-on training in radiological sciences 👩‍⚕️🧲. She has guided radiologic technologists, medical students, and postgraduates through innovative programs that incorporate cutting-edge technologies like PET/CT, proton therapy, and radiogenomics 💡🧬. Her dedication to advancing clinical competence is evident in the numerous experimental and clinical theses completed under her mentorship 📖🎓. By blending theory with real-world application, she has nurtured a generation of professionals equipped to meet the evolving challenges of diagnostic imaging and radiation therapy.

Research Focus 

Assoc. Prof. Dr. Angela Sardaro’s research focus lies at the intersection of oncologic radiotherapy, advanced diagnostic imaging, and radiation-induced toxicities 🎯🧲. Her work spans critical areas such as hypofractionated radiotherapy, prostate cancer, head and neck squamous cell carcinoma, breast cancer survivorship, and radiogenomics 📊🧬. She also investigates rare radiation-associated tumors like angiosarcomas, while leveraging cutting-edge tools like 18F-FCH PET/CT, MR imaging, and stereotactic radiosurgery 🧠🔬. Her systematic reviews and meta-analyses contribute to refining treatment protocols and improving patient outcomes 🩻👩‍⚕️. Dr. Sardaro’s impactful research bridges clinical innovation with evidence-based radiation oncology.

Publication Top Notes

  • Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
  • Nodal assessment and extranodal extension in head and neck squamous cell cancer: insights from computed tomography and magnetic resonance imaging
  • Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments
  • Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity
  • Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease
  • Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis
  • Role of 18F-FCH PET/CT in Detecting Recurrences of Prostate Cancer After Curative Treatments

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Published on by Top Pharmaceutical

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Mr. Jonathan Ejie, UCSF, United States

Mr. Jonathan Ejie is an aspiring physician-scientist currently pursuing his M.D. at UCSF 🩺 (Class of 2026), following a B.S. in Electrical Engineering & Computer Science from UC Berkeley 💻. His research spans oncology, radiology, and AI in healthcare, with published work in Cancers (2025) and upcoming studies in Nature Communications 📊. Jonathan integrates data science 🧠 with clinical insights, contributing to health equity, quality improvement, and surgical education. A mentor, tutor, and award-winning leader 🏅, he co-founded the UCSF Futbol Club and serves underserved communities through advocacy and outreach.

Publication Profile 

Orcid

Education

Mr. Jonathan Ejie is an exceptional scholar whose educational journey bridges medicine and technology. He is currently pursuing his Doctor of Medicine (M.D.) degree at the prestigious University of California, San Francisco (UCSF) 🏥, with an expected graduation in 2026. Prior to this, he earned a Bachelor of Science in Electrical Engineering and Computer Science (EECS) 💻 from the University of California, Berkeley, graduating in 2022. His strong foundation in both engineering and clinical science equips him with a unique interdisciplinary perspective 🤖🩺, positioning him at the forefront of innovation in digital health and precision medicine.

Experience

Mr. Jonathan Ejie brings a blend of academic support and compassionate service to his professional journey. As an MCAT Physics Tutor at UCSF (2023), he guided 15+ students through complex physics concepts 📘⚛️. Earlier, at Contra Costa College (2019–2021), he tutored mathematics from Algebra to Calculus ➕📐. His volunteer work includes providing first aid at athletic events 🏃‍♂️🩹, teaching surgical skills to high school students at UCSF 🧵🧑‍⚕️, and serving as a Health Advocate at West County Health Center 💬🩺, helping underserved patients access vital community resources. His dedication reflects a strong commitment to both education and public health.

Awards

Mr. Jonathan Ejie has been recognized for his academic excellence and impactful contributions to medicine and research. In 2024, he was honored with the prestigious Sinkler Miller Medical Association Scholarship 🎖️, sponsored by Gilead, celebrating his commitment to health equity and academic distinction. He also received the UCSF School of Medicine Summer Explore Fellowship Grant 🌟, supporting his innovative pursuits in medical research. In May 2023, Jonathan earned the Inquiry Conference Travel and Dissemination Award ✈️📊, which enabled him to share his scholarly findings on a larger stage. These accolades reflect his rising potential and leadership in healthcare.

Research Focus 

Mr. Jonathan Ejie’s research focus lies at the intersection of oncology, health disparities, and medical data science. His standout work on the “Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer” 📉🩺 highlights critical inequities in healthcare delivery across race, geography, and insurance status. Combining his background in medicine 🧑‍⚕️ and computer science 💻, Jonathan leverages data analysis and machine learning 🤖📊 to drive systemic improvements in cancer care. His work reflects a commitment to equity, evidence-based medicine, and the pursuit of personalized, accessible treatment strategies for vulnerable cancer populations.

Publication Top Notes

  • Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Published on by Top Pharmaceutical

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan

Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 🎓. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology 🏥. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) 📋. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.

Publication Profile 

Scopus

Education

Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan 🗾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 🎓. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology 🏥. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.

Awards

Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) 🇯🇵, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor 👨‍⚕️. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology 🏥, the Japan Society of Hepatology 🏆, and the Japan Gastroenterological Endoscopy Society 🔬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.

Experience

Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.

Research Focus

Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases 🏥, and vascular complications like gastric varices and Budd-Chiari syndrome 🫀. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes 🎯. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.

Publication Top Notes

  • Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration
  • Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
  • Black Esophagus in Hyperosmolar Hyperglycemic Syndrome
  • The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
  • Solitary Cardiac Metastasis of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome

Mario Romeo | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile 

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus 

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

  • Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis
  • Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review
  • Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?
  • Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
  • Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?
  • Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
  • FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis
  • Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report
  • Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?
  • Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Xinglong Zhong | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Xinglong Zhong | Cardiovascular Pharmacology | Best Researcher Award

Prof. Xinglong Zhong, Department of Cardiology, The Fourth Affiliated Hospital of Guangxi Medical University/Liuzhou Workers’ Hospital, China

Prof. Xinglong Zhong is a dedicated cardiologist specializing in the diagnosis and treatment of cardiovascular diseases, with expertise in independent coronary angiography. 🏥 His clinical practice is complemented by a strong research background, focusing on vascular aging, myocardial fibrosis, and vascular calcification. 🔬 He has co-authored multiple peer-reviewed papers in prestigious SCI-indexed journals and has accumulated 244 citations with a top paper cited 127 times. 📊 His innovative work bridges interventional cardiology and molecular research, positioning him as a rising figure in cardiovascular science and precision medicine. 🌐❤️ His efforts continue to advance heart health through scientific discovery.

Publication Profile  

Orcid

Education

Prof. Xinglong Zhong 🫀 is a skilled cardiologist specializing in the diagnosis and treatment of cardiovascular diseases, with particular expertise in independent coronary angiography. 🏥 His clinical proficiency is matched by a strong foundation in research, enabling him to bridge hands-on patient care with scientific innovation. 🔬 He has co-authored several peer-reviewed articles published in SCI-indexed journals, contributing valuable insights into vascular health and cardiology. 📚 His work exemplifies a harmonious integration of advanced interventional cardiology and active academic engagement, making him a vital contributor to both clinical excellence and medical research.

Professional Memberships

Prof. Xinglong Zhong 🩺 is currently not affiliated with any professional memberships or academic societies. While he does not hold formal memberships, his impactful research contributions and clinical expertise in cardiology speak volumes about his dedication to the field. 📚🧬 His work continues to gain recognition through high-quality publications and citation metrics, reflecting his independent commitment to advancing cardiovascular science. 🚀🔬 Despite the absence of organizational affiliations, Prof. Zhong remains a respected figure in both research and clinical communities, demonstrating that consistent innovation and scholarly excellence can shine through individual initiative and professional dedication.

Research Focus

Prof. Xinglong Zhong’s research focus lies in cardiovascular pathophysiology, with a special emphasis on vascular calcification, myocardial fibrosis, and molecular mechanisms of aging in chronic kidney disease. 🔍 His work explores the impact of gut-derived metabolites like trimethylamine-N-oxide (TMAO), inflammatory signaling pathways (NF-κB, NLRP3), and therapeutic agents such as puerarin and dihydromyricetin. 💊 He also investigates cutting-edge strategies like supramolecular hydrogels for cellular senescence and novel concepts like ion therapy in myocardial infarction. 🧪 His multidisciplinary approach bridges molecular cardiology and regenerative therapy, advancing precision treatment in heart and vascular diseases.

Publication Top Notes

  • Trimethylamine-N-oxide promotes vascular aging via inhibiting GATA4 degradation in chronic kidney disease rats
  • Enhanced fibrotic potential of COL1A1hiNR4A1low fibroblasts in ischemic heart revealed by transcriptional dynamics heterogeneity analysis at both bulk and single-cell levels
  • Lactobacillus rhamnosus GG aggravates vascular calcification in chronic kidney disease: A potential role for extracellular vesicles
  • Dihydromyricetin ameliorates vascular calcification in chronic kidney disease by targeting AKT signaling
  • Puerarin Alleviates Lipopolysaccharide-Induced Myocardial Fibrosis by Inhibiting PARP-1 to Prevent HMGB1-Mediated TLR4-NF-κB Signaling Pathway
  • Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals
  • β-Galactosidase instructed supramolecular hydrogelation for selective identification and removal of senescent cells

  • CDC42 promotes vascular calcification in chronic kidney disease

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Mr. Hiroyuki Minoura, Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Japan

Mr. Hiroyuki Minoura is a dedicated and accomplished researcher in computational biology and bioinformatics 🧬. With a solid academic foundation in science and technology 🎓, he has contributed to multiple research projects focused on systems pharmacology, precision medicine, and data-driven modeling 🧠. His work is widely cited in top scientific databases such as Scopus and Google Scholar 📊, and he has published in several high-impact journals 📝. Mr. Minoura is known for his interdisciplinary collaborations 🤝 and commitment to innovation in healthcare solutions. His research continues to bridge complex biological data and clinical applications for a better tomorrow.

Publication Profile 

Google Scholar

Education

Mr. Hiroyuki Minoura 🎓 has built a strong academic and professional foundation rooted in research and innovation. With a solid educational background and years of experience in scientific study, he has contributed meaningfully to his field. His commitment to advancing knowledge is reflected in his work on cutting-edge research projects and industry collaborations. 🧪 Through consistent scholarly output and a keen focus on impactful solutions, Mr. Minoura has established himself as a promising leader in the research community. 🌍 His achievements not only demonstrate academic excellence but also highlight his potential to drive future advancements in science and technology.

Research and Innovations

Mr. Hiroyuki Minoura 🧠 has made remarkable strides in the realm of research and innovation. With a portfolio that includes numerous completed and ongoing research projects 🔬, he has consistently contributed to scientific progress. His publications in indexed journals 📚 and his registered patents 📄 reflect a commitment to cutting-edge discovery and practical application. Mr. Minoura’s impressive citation index 📈 underscores the influence of his work in the academic community. Additionally, his involvement in industry-sponsored projects 🤝 showcases the relevance and impact of his research beyond academia. His innovative contributions continue to shape advancements across multiple scientific disciplines.

Research Focus

Mr. Hiroyuki Minoura’s research focus lies at the nexus of surgical oncology and gastroenterology, concentrating on upper gastrointestinal malignancies—particularly gastric and esophagogastric junction cancers. 🏥🔬 He investigates appetite‑preserving gastrectomy, safe esophago‑jejunal reconstructions, and molecular crosstalk between cancer‑associated fibroblasts and the TGF‑β pathway, aiming to craft organ‑sparing, patient‑centred therapies. 🍽️🧬 His studies span bench to bedside: from laparoscopic innovations and “parachute” anastomosis techniques 🩺✂️ to translational biomarker discovery for precision medicine. 📊💉 Minoura also evaluates systemic regimens like mFOLFIRINOX for metastatic cases, bridging surgery with chemotherapy. 🚀 His holistic, innovation‑driven approach advances outcomes for complex digestive cancers worldwide patient survival.

Publication Top Notes

luis Guerra Sánchez | Drug Safety and Risk Management | Outstanding Contribution Award

Published on by Top Pharmaceutical

luis Guerra Sánchez | Drug Safety and Risk Management | Outstanding Contribution Award

Dr. luis Guerra Sánchez, HGU Gregorio Marañon, Spain

Dr. Luis Guerra Sánchez is an esteemed Spanish nurse and researcher with a Ph.D. in Nursing Care Research 🎓 from Universidad Complutense de Madrid. With degrees in Nursing (Graduate & Diploma) 🏥 and a Master’s in Nursing Research, his academic journey reflects excellence and dedication. He has completed over 40 advanced professional trainings 🧠, specializing in chronic care, diabetes, neonatal intensive care, statistics, leadership, and biomedical research 📊🧪. Dr. Sánchez is deeply committed to healthcare innovation, evidence-based practice, and continuous learning, making significant contributions to nursing education and clinical practice. A true advocate for patient-centered care and professional growth.

Publication Profile 

Orcid

Education

Dr. Luis Guerra Sánchez holds a robust academic foundation in nursing, highlighted by a Ph.D. in Investigación en Cuidados de Enfermería 🎓 and a Master’s degree in Investigación en Cuidados from Universidad Complutense de Madrid 🏛️. His commitment to lifelong learning is evident in his completion of over 40 specialized training programs, covering diverse areas such as chronic patient care, diabetes management, neonatal intensive care, biomedical research, statistics, and healthcare leadership 📊🧪💉. With extensive experience in clinical and academic settings, Dr. Sánchez continues to contribute meaningfully to healthcare excellence and nursing advancement across Spain and beyond.

Awards

Dr. Luis Guerra Sánchez has pursued extensive professional development through a wide array of training programs and certifications 🎓. His credentials include courses in research methodology 🧪, statistical analysis 📊, and healthcare management 🏥. He holds specialized certifications in critical care 🚑, cardiology ❤️, and neonatology 👶, reflecting his deep commitment to high-level clinical expertise. With over four decades of continuous learning, his qualifications span from advanced clinical practices to leadership and teaching in healthcare. These achievements underline his dedication to excellence and innovation in patient care, nursing education, and evidence-based medical practice.

Experience

Dr. Luis Guerra Sánchez brings a wealth of experience in both clinical practice and scientific research 🏥📚. His professional journey spans diverse healthcare settings, where he has contributed significantly through patient care, management, and academic mentoring 👨‍⚕️👨‍🏫. With numerous certifications and continuous training in specialized areas such as cardiology, neonatology, and chronic disease management ❤️👶, he exemplifies lifelong learning. His involvement in research projects and data-driven healthcare innovations reflects a strong dedication to evidence-based practice and improving patient outcomes 🔎📈. Dr. Sánchez’s impact extends across clinical, educational, and investigative domains, making him a leader in modern nursing.

Research Focus

Dr. Luis Guerra Sánchez’s scholarship sits at the crossroads of clinical nutrition, cardiovascular nursing, and patient‑safety science. His randomized trials explore how tailored dietary strategies can reverse malnutrition, boost functional capacity, and elevate quality of life in chronic heart‑failure patients 🫀📈. Parallel work standardises intravenous therapies and analgesia–sedation practices in ICUs, tightening medication‑safety protocols 💉🔒. Through multicentre audits, he spotlights delirium, restraint use, and nutritional risk—generating evidence for nurse‑led interventions that cut complications and hospital days 🏥⏱️. Overall, Luis champions evidence‑based, nurse‑driven care models that fuse nutrition science with cardiology and critical‑care best practices, improving outcomes across vulnerable populations .

Publication Top Notes

  • Effect of a double nutritional intervention on the nutritional status, functional capacity, and quality of life of patients with chronic heart failure: 12-month results from a randomized clinical trial
  • Standardization and Chemical Characterization of Intravenous Therapy in Adult Patients: A Step Further in Medication Safety.
  • Assessment of analgesia, sedation, physical restraint and delirium in patients admitted to Spanish intensive care units. Proyecto ASCyD
  • Nutritional intervention in patients with heart failure. 3 month results of a clinical trial
  • [Prevalence of undernutrition in hospital patients with unbalanced heart failure; subjective global assessment like prognosis sign].

  • [Nutritional screening in heart failure patients: 5 methods review].